Final Results from a Phase I Trial Combining Selinexor with High-dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)
Final Results from a Phase I Trial Combining Selinexor with High-dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML)